Measuring the Effects of Drugs on Cancer Cells
A new approach established at the University of Zurich sheds light on the effects of anti-cancer drugs and the defense mechanisms of cancer cells. The method makes it possible to quickly test various drugs and treatment combinations at the cellular level.
Cancer cells are cells over which the human body has lost control. The fact that they are transformed body cells makes it all the more difficult to combat them effectively – whatever harms them usually also harms the healthy cells in the body. This is why it is important to find out about the cancer cells’ particular weaknesses.
In certain types of breast and ovarian cancer, for example, such a weakness is given by mutations in genes that play a role in DNA repair. Treating cancer cells of this kind with a group of newly approved drugs – so-called PARP inhibitors – makes it difficult for these cells to replicate their DNA, and they ultimately perish. Normal cells, however, can solve such problems using their intact DNA repair machinery.
Effect of drugs observed in thousands of cells
The Department of Molecular Mechanisms of Disease of the University of Zurich uses cancer cell cultures to investigate the exact effects of this new group of drugs. “Our method of fluorescence-based high-throughput microscopy allows us to observe precisely when and how a drug works in thousands of cells at the same time,” explains postdoc researcher Jone Michelena. Her measurements have revealed how PARP inhibitors lock their target protein in an inactive state on the cells’ DNA and how this complicates DNA replication, which in turn leads to DNA damage. If this damage is not repaired quickly, the cells can no longer replicate and eventually die.
The new approach enables researchers to analyze the initial reaction of cancer cells to PARP inhibitors with great precision. What’s special about the very sensitive procedure is the high number of individual cells that can be analyzed concurrently with high resolution using the automated microscopes at the Center for Microscopy and Image Analysis of UZH. Cancer cells vary and thus react differently to drugs depending on their mutations and the cell cycle phase they are in. The UZH researchers have now found a way to make these differences visible and quantify them precisely.
Rapid and precise testing of cancer cells
Outside of the laboratory, the success of PARP inhibitors and other cancer medication is complicated by the fact that in some patients the cancer returns – after a certain point, the cancer cells become resistant and no longer respond to the drugs. The high-throughput method employed by UZH researchers is particularly useful for this kind of problem: Cells can be tested in multiple conditions with short turnover times, and specific genes can be eliminated one by one in a targeted manner. Doing so can reveal which cell functions are needed for a certain drug to take effect.
In addition, mechanisms of drug combinations can be analyzed in great detail. In her study, Jone Michelena has already identified such a combination, which inhibits cancer cell proliferation to a significantly higher extent than the combination’s individual components by themselves. “We hope that our approach will make the search for strategies to combat cancer even more efficient,” says Matthias Altmeyer, head of the research group at the Department of Molecular Mechanisms of Disease at UZH.
Literature:
Jone Michelena, Aleksandra Lezaja, Federico Teloni, Thomas Schmid, Ralph Imhof, Matthias Altmeyer. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nature Communications. xxxx, 2018. DOI: 10.1038/s41467-018-05031-9
Link to UZH press release in English
Link to UZH press release in German
More news
- The Dutch Research Council (NOW) awarded a 2 year Rubicon grant to Dr. Yannick Kok for his project DNA repair: wrong place, wrong time
- Award Ceremony and Lectures Dr. Ernst Th. Jucker Preis 2019/2020 for Important Contributions to Cancer Research
- The project of the MSRU “Human-Horse Interaction” was awarded the “Prize for Educational Innovations” ”from the Hans-Peter Frey Foundation
- Kaivalya Walavalkar received the prestigious EMBO postdoctoral fellowship
- Scott Finlay PhD and Salim Darwiche PhD awarded first prize for best investor pitch, presenting their marketable product for cartilage repair
- Congratulations to SNSF Prof. Dr. Matthias Altmeyer for being appointed Associate Professor
- Congratulations to Prof.em. Dr. Brigitte von Rechenberg for obtaining ORS 2020 Women’s Leadership Forum Award
- Stephanie Lüthi receives semester price 2019 from VSF
- Prof. Dr. Tuncay Baubec receives ERC Consolidator Grant
- Ramon Pfändler receives semester price from MNF
- Nina Schmolka receives SNF Ambizione Fellowship
- New paper from group M. Altmeyer online in EMBO journal
- Molecular biologist Tuncay Baubec received the renowned Georg Friedrich Götz Award
- Preisgekrönte Nachwuchsforschung
- Verlängerung SNF Förderungsprofessur von Prof. Dr. Tuncay Baubec
- Erfolgsmeldung aus dem Department of Molecular Mechanisms of Disease
- Proteinveränderungen weisen auf Krebs hin
- Mass spectrometry method provides first view of stress-induced extracellular protein modification in cells and tissues
- Tumor Therapy of the Future
- Prolongation of SNSF Professorship for Prof. Dr. Matthias Altmeyer
- Raffaella Santoro received the prestigious ERC advanced grant
- Article in UZH Magazin about Matthias Altmeyer on his work "Krebszellen im Burnout"
- Successful and stimulating 3rd Joint Department Colloquium (JDC) of the DMMD
- Important Mechanism of Epigenetic Gene Regulation Identified
- UZH press release on the work of Santoro and Cinelli groups on stem cell pluripotency in Nature Cell Biology
- Professorial appointment process successfully completed
- SNF Prof. Dr. Matthias Altmeyer receives highly prestigious ERC Starting Grant
- Dr. Francisco Verdeguer new group leader at DMMD
- Prof. Dr. Raffaella Santoro elected as new EMBO member
- Dr. Sandra Frommel from the Santoro group receives Jahrespreis of the Vetsuisse Faculty
- Group van Loon publishes on the impact of ribonucleotide incorporation on DNA base excision repair in Nature Communications
- Dr. Barbara van Loon appointed to Associate Professor position at the Norwegian University for Science and Technology
- IVBMB is now Department of Molecular Mechanisms of Disease (DMMD)
- Group Hottiger publishes on identification of genome-wide chromatin ADP-riboslyation in Molecular Cell
- Group Altmeyer publishes on intracellular phase separation in Nature Communications
- IVBMB now also associated with Faculty of Science (MNF)
- Dr. Tuncay Baubec awarded SNF-professorship to be carried out at the IVBMB
- Group Santoro awarded for Cell Stem Cell Cover Page
- Group Santoro publishes major study on predictive marker of prostate cancer recurrence in Nature Genetics
- Dr. Matthias Altmeyer awarded SNF-professorship to be carried out at the IVBMB
- Prof. Michael O. Hottiger new acting director of IVBMB as of 1. February 2014